Accurately identifying cirrhosis and its complications to create the novel statewide Indiana digital cirrhosis registry

准确识别肝硬化及其并发症,以建立全新的印第安纳州全州数字肝硬化登记系统。

阅读:2

Abstract

Administrative datasets are important for cirrhosis research but limited by suboptimal cirrhosis identification. We developed and validated algorithms to accurately identify cirrhosis and its complications in real-world, statewide dataset. From 2017 to 2020 Indiana Patient Care Network data, 15,636 records were grouped by combinations of code and lab criteria (group A: cirrhosis codes, B: FIB-4/APRI criteria, C: cirrhosis complication codes, D: code/lab for liver disease). Diagnoses were confirmed by chart review in 4.5% of 15,636 records. Positive predictive values (PPV) were calculated for various algorithms which were externally validated in hepatology clinic (n = 1,039) and emergency department-based cirrhosis cohorts (n = 2,124). Charts meeting criteria for group A and at least one other group (“AX”, e.g., ABC) had an overall PPV of 86%. Highest PPVs were seen in ACD and ABCD and confirmed during external validation: 88% and 97% (hepatology cohort), 79% and 93% (ED cohort). Without complication codes, ABD showed strong PPVs: 86%(internal), 92%(hepatology), 72%(ED). ICD-10-based definitions alone were suboptimal for complications: ascites (57%), hepatic encephalopathy (HE:55%). PPV for HE was improved with addition of medications but remained < 80%. Taken together, we provide algorithms to identify both compensated and decompensated cirrhosis in real-world data. Using the “AX” algorithm, we created the statewide Indiana Digital Cirrhosis Cohort to support future research across cirrhosis stages. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-026-39585-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。